Drugs that improve hyperphosphatemia in patients with chronic kidney disease are undergoing a generation change in the domestic market.

Following the launch of the new drug Nephoxil Cap (ferric citrate, Kyowa Kirin Korea) last year, generic drugs containing sevelamer have continued to grow, and news of the withdrawal of existing drugs is also arising.

According to industry sources on the 18th, Fosrenol Tab (lanthanum carbonate), which was supplied by JW Pharmaceuticals in Korea, will be discontinued. Fosrenol has been imported and sold by JW Pharmaceuticals from Takeda. With the termination of the supply contract, its supply to the domestic market is expected to be gradually discontinu